Gino DiCaro

More restrictions proposed on pseudoephedrine

By Gino DiCaro, VP, Communications

Capitol Update, May 21, 2009 Share this on FacebookTweet thisEmail this to a friend

On May 26th, the Senate Appropriations Committee will consider SB 484 (Rod Wright, D-Los Angeles) which could increase the cost of healthcare coverage for everyone by forcing individuals to obtain a prescription for products which are now available without a prescription.

SB 484 seeks to address the illegal manufacture of methamphetamine by restricting access to a necessary ingredient for its manufacture – pseudoephedrine (PSE). Currently, retailers are required by law to restrict the quantity sold and to record information about purchasers of PSE in order to prevent illegal diversion to methamphetamine production. This bill would eliminate reasonable access to PSE in any over-the-counter sale and require a prescription to obtain it.

CMTA supports effective federal and state sales restrictions to prevent the illegal diversion of over-the-counter pseudoephedrine (PSE) for manufacturing methamphetamine. However, these measures must strike the proper balance to allow access to these products for their legitimate medical uses. While we applaud the author’s intention to reduce crime, requiring prescription status for PSE would mean substantial new costs for legitimate consumers, measured in both time and money, to access important and needed medicines.  

CMTA is opposed to this measure.
Read more Safety & Health articles

Capitol updates archive 989898989